Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CATALYST PHARMACEUTICALS, INC. Director's Dealing 2022

Nov 17, 2022

31542_dirs_2022-11-17_23dea615-a3cc-4ae0-a193-81ce9db95992.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2022-11-15

Reporting Person: O'Keeffe Charles B (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-11-15 Common stock, par value $0.001 per share S 87985 $16.037 Acquired 565057 Direct

Footnotes

F1: Shares were sold for personal reasons and not as a result of any disagreement with the Company. Mr. O'Keeffe remains an officer of the Company.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $16.00 to $16.18 per share.